{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:26:26Z","timestamp":1790796386451,"version":"4.1.0"},"reference-count":68,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2014.0069","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:19:26Z","timestamp":1525252766000},"source":"Crossref","is-referenced-by-count":38,"title":["The Treatment of Type 2 Diabetes"],"prefix":"10.3238","author":[{"given":"Andreas F. H.","family":"Pfeiffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald H.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2014,1,31]]},"reference":[{"key":"10.3238\/arztebl.2014.0069_ref1","doi-asserted-by":"crossref","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, et al.: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577\u201396.","DOI":"10.1007\/s00125-012-2534-0"},{"key":"10.3238\/arztebl.2014.0069_ref2","doi-asserted-by":"crossref","unstructured":"DeFronzo RA: Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53: 1270\u201387.","DOI":"10.1007\/s00125-010-1684-1"},{"key":"10.3238\/arztebl.2014.0069_ref3","unstructured":"Paulweber B, Valensi P, Lindstrom J, et al.: A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res 2010; 42(Suppl 1): 3\u201336."},{"key":"10.3238\/arztebl.2014.0069_ref4","doi-asserted-by":"crossref","unstructured":"Imamura M, Maeda S. Genetics of type 2 diabetes: the GWAS era and future perspectives. Endocr J 2011; 58: 723\u201339.","DOI":"10.1507\/endocrj.EJ11-0113"},{"key":"10.3238\/arztebl.2014.0069_ref5","doi-asserted-by":"crossref","unstructured":"Europe I: The International Diabetes Federation. Diabetes Atlas. 2009; 4th edition: www.idf.org\/atlasmap\/atlasmap (Last accessed on 13 Januaray 2014)","DOI":"10.1016\/S1499-2671(09)31002-3"},{"key":"10.3238\/arztebl.2014.0069_ref6","doi-asserted-by":"crossref","unstructured":"Seshasai SR, Kaptoge S, Thompson A, et al.: Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011; 364: 829\u201341.","DOI":"10.1056\/NEJMoa1008862"},{"key":"10.3238\/arztebl.2014.0069_ref7","doi-asserted-by":"crossref","unstructured":"Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M: Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993; 77: 1287\u201393.","DOI":"10.1210\/jcem.77.5.8077323"},{"key":"10.3238\/arztebl.2014.0069_ref8","doi-asserted-by":"crossref","unstructured":"Markovic TP, Jenkins AB, Campbell LV, Furler SM, Kraegen EW, Chisholm DJ: The determinants of glycemic responses to diet restriction and weight loss in obesity and NIDDM. Diabetes Care 1998; 21: 687\u201394.","DOI":"10.2337\/diacare.21.5.687"},{"key":"10.3238\/arztebl.2014.0069_ref9","doi-asserted-by":"crossref","unstructured":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837\u201353.","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"10.3238\/arztebl.2014.0069_ref10","doi-asserted-by":"crossref","unstructured":"Wing RR, Lang W, Wadden TA, et al.: Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes. Diabetes Care 2011; 34: 1481\u20136.","DOI":"10.2337\/dc10-2415"},{"key":"10.3238\/arztebl.2014.0069_ref11","doi-asserted-by":"crossref","unstructured":"Wing RR: Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 2010; 170: 1566\u201375.","DOI":"10.1001\/archinternmed.2010.334"},{"key":"10.3238\/arztebl.2014.0069_ref12","doi-asserted-by":"crossref","unstructured":"Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R: Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011; 54: 2506\u201314.","DOI":"10.1007\/s00125-011-2204-7"},{"key":"10.3238\/arztebl.2014.0069_ref13","doi-asserted-by":"crossref","unstructured":"Selvin E, Steffes MW, Zhu H, et al.: Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 2010; 362: 800\u201311.","DOI":"10.1056\/NEJMoa0908359"},{"key":"10.3238\/arztebl.2014.0069_ref14","doi-asserted-by":"crossref","unstructured":"Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care 2010; 33(Suppl 1): 3.","DOI":"10.2337\/dc10-S003"},{"key":"10.3238\/arztebl.2014.0069_ref15","doi-asserted-by":"crossref","unstructured":"Kerner W, Br\u00fcckel J: Definition, Klassifikation und Diagnostik des Diabetes mellitus. Diabetologie 2011; Suppl 2: 107\u201310.","DOI":"10.1055\/s-0031-1283764"},{"key":"10.3238\/arztebl.2014.0069_ref16","doi-asserted-by":"crossref","unstructured":"Ohkubo Y, Kishikawa H, Araki E, et al.: Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103\u201317.","DOI":"10.1016\/0168-8227(95)01064-K"},{"key":"10.3238\/arztebl.2014.0069_ref17","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS): X. Urinary albumin excretion over 3 years in diet-treated type 2, (non-insulin-dependent) diabetic patients, and association with hypertension, hyperglycaemia and hypertriglyceridaemia. Diabetologia 1993; 36: 1021\u20139.","DOI":"10.1007\/BF02374494"},{"key":"10.3238\/arztebl.2014.0069_ref18","doi-asserted-by":"crossref","unstructured":"Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560\u201372.","DOI":"10.1056\/NEJMoa0802987"},{"key":"10.3238\/arztebl.2014.0069_ref19","unstructured":"Giani G, Janka HU, Hauner H, et al.: Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. Evidenzbasierte Leitlinie DDG \u2013 Aktualisierung 05\/2004. www.deutsche-diabetes-gesellschaft.de\/fileadmin\/Redakteur\/Leitlinien\/Evidenzbasierte_ Leitlinien\/EBL_Epidemiologie_Update_2004.pdf (last accessed on 9 October 2013)."},{"key":"10.3238\/arztebl.2014.0069_ref20","doi-asserted-by":"crossref","unstructured":"Gerstein HC, Miller ME, Genuth S, et al.: Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818\u201328.","DOI":"10.1056\/NEJMoa1006524"},{"key":"10.3238\/arztebl.2014.0069_ref21","doi-asserted-by":"crossref","unstructured":"Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129\u201339.","DOI":"10.1056\/NEJMoa0808431"},{"key":"10.3238\/arztebl.2014.0069_ref22","doi-asserted-by":"crossref","unstructured":"Ray KK, Seshasai SR, Wijesuriya S, et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765\u201372.","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"10.3238\/arztebl.2014.0069_ref23","doi-asserted-by":"crossref","unstructured":"Hemmingsen B, Lund SS, Gluud C, et al.: Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011; 343: d6898.","DOI":"10.1136\/bmj.d6898"},{"key":"10.3238\/arztebl.2014.0069_ref24","unstructured":"IQWiG. Nutzenbewertung einer langfristigen normnahen Blutzuckersenkung bei Patienten mit Diabetes mellitus Typ 2. IQWiG-Berichte \u2013 Jahr: 2011 Nr. 87 2011; www.iqwig.de\/download\/ A05\u201307_Rapid-Report_Normnahe-Blutzuckersenkung-bei-Diabetes- mellitus-Typ-2.pdf (last accessed on 16 September 2012)."},{"key":"10.3238\/arztebl.2014.0069_ref25","doi-asserted-by":"crossref","unstructured":"Zannad F, Stough WG, Pocock SJ, et al.: Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements? Eur Heart J 2012; 33: 1049\u201357.","DOI":"10.1093\/eurheartj\/ehr437"},{"key":"10.3238\/arztebl.2014.0069_ref26","doi-asserted-by":"crossref","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577\u201389.","DOI":"10.1056\/NEJMoa0806470"},{"key":"10.3238\/arztebl.2014.0069_ref27","unstructured":"Bundes\u00e4rztekammer (B\u00c4K), Kassen\u00e4rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF): Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes\u2013Langfassung, 1st edition, Version 2. 2013 last updated on September 2013 Available from: www.versorgungsleitlinien.de\/themen\/diabetes2\/dm2_Therapie (last accessed on 11. January 2014)."},{"key":"10.3238\/arztebl.2014.0069_ref28","doi-asserted-by":"crossref","unstructured":"Matthaei S, Bierwirth R, Fritsche A, et al.: Medikament\u00f6se antihyperglyk\u00e4mische Therapie des Diabetes mellitus Typ 2. Update der evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft. Exp Clin Endocrinol Diabetes 2009; 117: 522\u201357.","DOI":"10.1055\/s-0028-1098798"},{"key":"10.3238\/arztebl.2014.0069_ref29","doi-asserted-by":"crossref","unstructured":"Sacks DB, Arnold M, Bakris GL, et al.: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 2011; 34: e61\u2013e99.","DOI":"10.2337\/dc11-9998"},{"key":"10.3238\/arztebl.2014.0069_ref30","doi-asserted-by":"crossref","unstructured":"American Diabetes Association: Standards of medical care in diabetes\u20142011. Diabetes Care 2011; 34(Suppl 1): 11\u201361.","DOI":"10.2337\/dc11-S011"},{"key":"10.3238\/arztebl.2014.0069_ref31","doi-asserted-by":"crossref","unstructured":"Gross JL, Kramer CK, Leitao CB, et al.: Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011; 154: 672\u20139.","DOI":"10.7326\/0003-4819-154-10-201105170-00007"},{"key":"10.3238\/arztebl.2014.0069_ref32","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"10.3238\/arztebl.2014.0069_ref33","doi-asserted-by":"crossref","unstructured":"Monami M, Colombi C, Balzi D, et al.: Metformin and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 2011; 34: 129\u201331.","DOI":"10.2337\/dc10-1287"},{"key":"10.3238\/arztebl.2014.0069_ref34","doi-asserted-by":"crossref","unstructured":"Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800 000 individuals. BMC Cancer 2011; 11: 20.","DOI":"10.1186\/1471-2407-11-20"},{"key":"10.3238\/arztebl.2014.0069_ref35","doi-asserted-by":"crossref","unstructured":"Shaw JS, Wilmot RL, Kilpatrick ES: Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160\u20133.","DOI":"10.1111\/j.1464-5491.2007.02221.x"},{"key":"10.3238\/arztebl.2014.0069_ref36","doi-asserted-by":"crossref","unstructured":"Herrington WG, Levy JB: Metformin: effective and safe in renal disease? Int Urol Nephrol 2008; 40: 411\u20137.","DOI":"10.1007\/s11255-008-9371-6"},{"key":"10.3238\/arztebl.2014.0069_ref37","doi-asserted-by":"crossref","unstructured":"Salpeter SR, Greyber E, Pasternak GA, Salpeter EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: CD002967.","DOI":"10.1002\/14651858.CD002967.pub4"},{"key":"10.3238\/arztebl.2014.0069_ref38","doi-asserted-by":"crossref","unstructured":"Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010: CD002967.","DOI":"10.1002\/14651858.CD002967.pub3"},{"key":"10.3238\/arztebl.2014.0069_ref39","doi-asserted-by":"crossref","unstructured":"Holstein A, Plaschke A, Egberts EH: Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001; 17: 467\u201373.","DOI":"10.1002\/dmrr.235"},{"key":"10.3238\/arztebl.2014.0069_ref40","doi-asserted-by":"crossref","unstructured":"Murata GH, Duckworth WC, Hoffman RM, Wendel CS, Mohler MJ, Shah JH: Hypoglycemia in type 2 diabetes: a critical review. Biomed Pharmacother 2004; 58: 551\u20139.","DOI":"10.1016\/j.biopha.2004.09.001"},{"key":"10.3238\/arztebl.2014.0069_ref41","doi-asserted-by":"crossref","unstructured":"Currie CJ, Peters JR, Tynan A, et al.: Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010; 375: 481\u20139.","DOI":"10.1016\/S0140-6736(09)61969-3"},{"key":"10.3238\/arztebl.2014.0069_ref42","doi-asserted-by":"crossref","unstructured":"Tzoulaki I, Molokhia M, Curcin V, et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339:b 4731.","DOI":"10.1136\/bmj.b4731"},{"key":"10.3238\/arztebl.2014.0069_ref43","doi-asserted-by":"crossref","unstructured":"Schramm TK, Gislason GH, Vaag A, et al.: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011; 32: 1900\u20138.","DOI":"10.1093\/eurheartj\/ehr077"},{"key":"10.3238\/arztebl.2014.0069_ref44","doi-asserted-by":"crossref","unstructured":"Rao AD, Kuhadiya N, Reynolds K, Fonseca VA: Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? a meta-analysis of observational studies. Diabetes Care 2008; 31:1672\u20138.","DOI":"10.2337\/dc08-0167"},{"key":"10.3238\/arztebl.2014.0069_ref45","doi-asserted-by":"crossref","unstructured":"Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427\u201343.","DOI":"10.1056\/NEJMoa066224"},{"key":"10.3238\/arztebl.2014.0069_ref46","doi-asserted-by":"crossref","unstructured":"White WB, Cannon CP, Heller SR, et al.: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327\u201335.","DOI":"10.1056\/NEJMoa1305889"},{"key":"10.3238\/arztebl.2014.0069_ref47","doi-asserted-by":"crossref","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al.: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317\u201326.","DOI":"10.1056\/NEJMoa1307684"},{"key":"10.3238\/arztebl.2014.0069_ref48","doi-asserted-by":"crossref","unstructured":"van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154\u201363.","DOI":"10.2337\/diacare.28.1.154"},{"key":"10.3238\/arztebl.2014.0069_ref49","doi-asserted-by":"crossref","unstructured":"Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A: Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: 1369.","DOI":"10.1136\/bmj.e1369"},{"key":"10.3238\/arztebl.2014.0069_ref50","unstructured":"Campbell RK, Cobble ME, Reid TS, Shomali ME: Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. J Fam Pract 2010; 59: 5\u20139."},{"key":"10.3238\/arztebl.2014.0069_ref51","doi-asserted-by":"crossref","unstructured":"Bennett WL, Maruthur NM, Singh S, et al.: Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011; 154: 602\u201313.","DOI":"10.7326\/0003-4819-154-9-201105030-00336"},{"key":"10.3238\/arztebl.2014.0069_ref52","doi-asserted-by":"crossref","unstructured":"Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696\u2013705.","DOI":"10.1016\/S0140-6736(06)69705-5"},{"key":"10.3238\/arztebl.2014.0069_ref53","doi-asserted-by":"crossref","unstructured":"Liu SC, Tu YK, Chien MN, Chien KL: Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012; 14: 810\u201320.","DOI":"10.1111\/j.1463-1326.2012.01606.x"},{"key":"10.3238\/arztebl.2014.0069_ref54","doi-asserted-by":"crossref","unstructured":"Gallwitz B, Guzman J, Dotta F, et al.: Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet 2012; 379: 2270\u20138.","DOI":"10.1016\/S0140-6736(12)60479-6"},{"key":"10.3238\/arztebl.2014.0069_ref55","doi-asserted-by":"crossref","unstructured":"Diamant M, Van Gaal L, Stranks S, et al.: Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks. Diabetes Care 2012; 35: 683\u20139.","DOI":"10.2337\/dc11-1233"},{"key":"10.3238\/arztebl.2014.0069_ref56","doi-asserted-by":"crossref","unstructured":"Drucker DJ, Sherman SI, Bergenstal RM, Buse JB: The safety of incretin-based therapies\u2014review of the scientific evidence. J Clin Endocrinol Metab 2011; 96: 2027\u201331.","DOI":"10.1210\/jc.2011-0599"},{"key":"10.3238\/arztebl.2014.0069_ref57","doi-asserted-by":"crossref","unstructured":"Spranger J, Gundert-Remy U, Stammschulte T. GLP-1-based therapies: the dilemma of uncertainty. Gastroenterology 2011; 141: 20\u20133.","DOI":"10.1053\/j.gastro.2011.05.019"},{"key":"10.3238\/arztebl.2014.0069_ref58","doi-asserted-by":"crossref","unstructured":"Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733\u201345.","DOI":"10.1111\/j.1463-1326.2007.00744.x"},{"key":"10.3238\/arztebl.2014.0069_ref59","doi-asserted-by":"crossref","unstructured":"Vaag A, Lund SS: Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol 2012; 166: 159\u201370.","DOI":"10.1530\/EJE-11-0022"},{"key":"10.3238\/arztebl.2014.0069_ref60","doi-asserted-by":"crossref","unstructured":"Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083\u201391.","DOI":"10.2337\/diacare.28.5.1083"},{"key":"10.3238\/arztebl.2014.0069_ref61","doi-asserted-by":"crossref","unstructured":"Zinman B, Gerich J, Buse JB, et al.: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224\u201330.","DOI":"10.2337\/dc08-2124"},{"key":"10.3238\/arztebl.2014.0069_ref62","doi-asserted-by":"crossref","unstructured":"Bell DS, Dharmalingam M, Kumar S, Sawakhande RB: Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II). Diabetes Obes Metab 2011;13: 800\u20135.","DOI":"10.1111\/j.1463-1326.2011.01408.x"},{"key":"10.3238\/arztebl.2014.0069_ref63","doi-asserted-by":"crossref","unstructured":"Pontiroli AE, Miele L, Morabito A: Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis. Diabetes Obes Metab 2012; 14: 433\u201346.","DOI":"10.1111\/j.1463-1326.2011.01543.x"},{"key":"10.3238\/arztebl.2014.0069_ref64","doi-asserted-by":"crossref","unstructured":"Davidson MB, Raskin P, Tanenberg RJ, Vlajnic A, Hollander P: A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure. Endocr Pract. 2011; 17: 395\u2013403.","DOI":"10.4158\/EP10323.OR"},{"key":"10.3238\/arztebl.2014.0069_ref65","doi-asserted-by":"crossref","unstructured":"Mann JI, De Leeuw I, Hermansen K, et al.: Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutr Metab Cardiovasc Dis 2004;14: 373\u201394.","DOI":"10.1016\/S0939-4753(04)80028-0"},{"key":"10.3238\/arztebl.2014.0069_ref66","unstructured":"Toeller M: Evidenzbasierte Ern\u00e4hrungsempfehlungen zur Behandlung und Pr\u00e4vention des Diabetes mellitus. Diabetes und Stoffwechsel 2005; 14: 75\u201394."},{"key":"10.3238\/arztebl.2014.0069_ref67","doi-asserted-by":"crossref","unstructured":"Wadden TA, Neiberg RH, Wing RR, et al.: Four-Year weight losses in the look AHEAD study: Factors associated with long-term success. Obesity 2011; 19: 1987\u201398.","DOI":"10.1038\/oby.2011.230"},{"key":"10.3238\/arztebl.2014.0069_ref68","doi-asserted-by":"crossref","unstructured":"Mancia G, Laurent S, Agabiti-Rosei E, et al.: Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121\u201358.","DOI":"10.1097\/HJH.0b013e328333146d"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T13:11:45Z","timestamp":1638796305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2014.0069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,31]]},"references-count":68,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2014.0069","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,31]]}}}